This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (164)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatology  • Dermatologic Disorders  • Randomized Controlled Trial  • Psoriasis  • Alert me on articles by topic  Social Bookmarking   What's this?

Alice B. Gottlieb, MD, PhD; Robert T. Matheson, MD; Nicholas Lowe, MD; Gerald G. Krueger, MD; Sewon Kang, MD; Bernard S. Goffe, MD; Anthony A. Gaspari, MD; Mark Ling, MD, PhD; Gerald D. Weinstein, MD; Anjuli Nayak, MD; Kenneth B. Gordon, MD, PhD; Ralph Zitnik, MD

Arch Dermatol. 2003;139:1627-1632.

Objective  To determine safety and efficacy of monotherapy with etanercept.

Design  Randomized, double-blind, placebo-controlled, multicenter study.

Setting  Outpatient, ambulatory; private practice and university dermatology research centers.

Patients  Patients aged at least 18 years, with plaque psoriasis involving 10% or more of body surface area; 148 were screened and 112 were randomly assigned to treatment groups and received study drug.

Interventions  Patients received placebo or etanercept, 25 mg, subcutaneously twice a week for 24 weeks. Other psoriasis therapies were limited during the study.

Main Outcome Measures  Safety measurements included tracking of adverse events and laboratory values. Efficacy was evaluated using the Psoriasis Area and Severity Index (PASI); the primary end point was a 75% improvement in PASI. Other efficacy measurements included patient and physician global assessments and quality-of-life measures.

Results  After 12 weeks of treatment, 17 (30%) of the 57 etanercept-treated patients and 1 (2%) of the 55 placebo-treated patients had achieved PASI 75%, and after 24 weeks, 32 (56%) of etanercept-treated patients and 3 (5%) of placebo-treated patients had reached this level (P<.001 for both time points). By 24 weeks, psoriasis was clear or minimal by physician's global assessment in more than 50% of patients who received etanercept. Treatment failure (PASI response <50) occurred in 23% of patients at week 24. All other measures confirmed the efficacy of etanercept. Adverse events were similar among etanercept and placebo groups.

Conclusion  Etanercept monotherapy provided significant benefit to patients with psoriasis and had a favorable safety profile.

From the University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, New Brunswick (Dr Gottlieb); Oregon Medical Research Center, Portland (Dr Matheson); Southern California Dermatology, Santa Monica (Dr Lowe); Department of Dermatology, University of Utah Medical Center, Salt Lake City (Dr Krueger); University of Michigan Medical Center, Taubman Center, Ann Arbor (Dr Kang); Minor and James Medical, Seattle, Wash (Dr Goffe); University of Maryland, Baltimore (Dr Gaspari); MedaPhase Inc, Newnan, Ga (Dr Ling); University of California, Irvine, UCI Gottschalk Medical Plaza, Medical Science I, Irvine (Dr Weinstein); Innovative Clinical Solutions, Bloomington, Ill (Dr Nayak); Division of Dermatology, Loyola University Medical Center, Maywood, Ill (Dr Gordon); and Amgen, Inc, Thousand Oaks, Calif (Dr Zitnik). Dr Zitnik is an employee of Amgen.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial
Raghu et al.
Am. J. Respir. Crit. Care Med. 2008;178:948-955.
ABSTRACT | FULL TEXT  

Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis: Results of a Randomized, Placebo-Controlled, Phase 2 Trial
Kimball et al.
Arch Dermatol 2008;144:200-207.
ABSTRACT | FULL TEXT  

Etanercept Treatment for Children and Adolescents with Plaque Psoriasis
Paller et al.
NEJM 2008;358:241-251.
ABSTRACT | FULL TEXT  

Use of Biological Agents in Patients With Moderate to Severe Psoriasis: A Cohort-Based Perspective
Jones-Caballero et al.
Arch Dermatol 2007;143:846-850.
ABSTRACT | FULL TEXT  

Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis
Tyring et al.
Arch Dermatol 2007;143:719-726.
ABSTRACT | FULL TEXT  

Psoriasis and Pustular Dermatitis Triggered by TNF-{alpha} Inhibitors in Patients With Rheumatologic Conditions
de Gannes et al.
Arch Dermatol 2007;143:223-231.
ABSTRACT | FULL TEXT  

Modeling the Exposure-Response Relationship of Etanercept in the Treatment of Patients With Chronic Moderate to Severe Plaque Psoriasis
Hutmacher et al.
J Clin Pharmacol 2007;47:238-248.
ABSTRACT | FULL TEXT  

Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks
Davis et al.
Ann Rheum Dis 2005;64:1557-1562.
ABSTRACT | FULL TEXT  

TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques
Gottlieb et al.
J. Immunol. 2005;175:2721-2729.
ABSTRACT | FULL TEXT  

Successful Treatment of Recalcitrant Pemphigus Vulgaris and Pemphigus Vegetans With Etanercept and Carbon Dioxide Laser
Lin et al.
Arch Dermatol 2005;141:680-682.
FULL TEXT  

Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies
Rott and Mrowietz
BMJ 2005;330:716-720.
FULL TEXT  

Immunopathology of psoriasis and psoriatic arthritis
Veale et al.
Ann Rheum Dis 2005;64:ii26-ii29.
ABSTRACT | FULL TEXT  

Psoriasis assessment tools in clinical trials
Feldman and Krueger
Ann Rheum Dis 2005;64:ii65-ii68.
ABSTRACT | FULL TEXT  

TNF{alpha} therapy in psoriatic arthritis and psoriasis
Mease
Ann Rheum Dis 2004;63:755-758.
FULL TEXT